|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | T0\* | T3 | T6 | T9 | Last FU\* | *p value\** |
| OC |

|  |
| --- |
| 41.5 |
| (± 22.9) |

 |

|  |
| --- |
| 13.5 |
| (± 7.0) |

 |

|  |
| --- |
| 9.9 |
| (± 2.5) |

 |

|  |
| --- |
| 6.8 |
| (± 2.7) |

 |

|  |
| --- |
| 6.7 |
| (± 2.3) |

 | *p=0.0001* |
| BAP |

|  |
| --- |
| 19.5 |
| (± 4.9) |

 |

|  |
| --- |
| 9.4 |
| (± 0.75) |

 |

|  |
| --- |
| 8.9 |
| (± 0.48) |

 |

|  |
| --- |
| 7.7 |
| (± 0.99) |

 |

|  |
| --- |
| 8.2 |
| (± 0.68) |

 | *p=0.0001* |
| β-CTX |

|  |
| --- |
| 0.498 |
| (± 0.107) |

 |

|  |
| --- |
| 0.034 |
| (± 0.001) |

 |

|  |
| --- |
| 0.033 |
| (± 0.001) |

 |

|  |
| --- |
| 0.033 |
| (± 0.001) |

 |

|  |
| --- |
| 0.084 |
| (± 0.055) |

 | *p=0.0001* |

Supplemental Table 2. Bone turnovers markers trend (evaluated every three months) during denosumab treatment (a single 60 mg dose every six month). The p Value is referred to the difference between last follow-up value and basal value (T0). The values are represented by mean value and standard deviation.